SG10201806854XA - Compositions comprising 15-ohepa and methods of using the same - Google Patents
Compositions comprising 15-ohepa and methods of using the sameInfo
- Publication number
- SG10201806854XA SG10201806854XA SG10201806854XA SG10201806854XA SG10201806854XA SG 10201806854X A SG10201806854X A SG 10201806854XA SG 10201806854X A SG10201806854X A SG 10201806854XA SG 10201806854X A SG10201806854X A SG 10201806854XA SG 10201806854X A SG10201806854X A SG 10201806854XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- ohepa
- compositions
- same
- fatty liver
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1301626.6A GB201301626D0 (en) | 2013-01-30 | 2013-01-30 | Composition comprising 15-OHEPA and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201806854XA true SG10201806854XA (en) | 2018-09-27 |
Family
ID=47891001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806854XA SG10201806854XA (en) | 2013-01-30 | 2014-01-24 | Compositions comprising 15-ohepa and methods of using the same |
| SG11201505457PA SG11201505457PA (en) | 2013-01-30 | 2014-01-24 | Compositions comprising 15-ohepa and methods of using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505457PA SG11201505457PA (en) | 2013-01-30 | 2014-01-24 | Compositions comprising 15-ohepa and methods of using the same |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20150224076A1 (ru) |
| EP (2) | EP2762143B1 (ru) |
| JP (2) | JP6363104B2 (ru) |
| KR (5) | KR20240011872A (ru) |
| CN (2) | CN105120872B (ru) |
| AU (2) | AU2014211628B2 (ru) |
| BR (1) | BR112015018270A2 (ru) |
| CA (1) | CA2897343C (ru) |
| CY (1) | CY1117209T1 (ru) |
| DK (1) | DK2762143T3 (ru) |
| ES (2) | ES2759448T3 (ru) |
| GB (1) | GB201301626D0 (ru) |
| HK (1) | HK1200351A1 (ru) |
| HR (1) | HRP20160203T1 (ru) |
| HU (1) | HUE026901T2 (ru) |
| IL (3) | IL239893A (ru) |
| MX (2) | MX364646B (ru) |
| NZ (1) | NZ709803A (ru) |
| PH (1) | PH12015501582B1 (ru) |
| PL (1) | PL2762143T3 (ru) |
| PT (1) | PT2762143E (ru) |
| RS (1) | RS54584B1 (ru) |
| RU (2) | RU2671208C2 (ru) |
| SG (2) | SG10201806854XA (ru) |
| SI (1) | SI2762143T1 (ru) |
| SM (1) | SMT201600069B (ru) |
| WO (1) | WO2014118097A1 (ru) |
| ZA (2) | ZA201505018B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US10017453B2 (en) | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| AU2015204531B2 (en) * | 2014-01-10 | 2019-11-14 | Afimmune Limited | Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| JP2018502163A (ja) * | 2015-01-16 | 2018-01-25 | アフィミューン リミテッド | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
| WO2016173923A1 (en) | 2015-04-28 | 2016-11-03 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| ES2851525T3 (es) * | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| AU2016370626B2 (en) * | 2015-12-18 | 2020-08-20 | Afimmune Limited | Compositions comprising 15-HEPE and methods of using the same |
| CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| CN115215725A (zh) * | 2021-04-15 | 2022-10-21 | 宋晓瑜 | 一种制备乙酸薰衣草酯及薰衣草醇的方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| ES2112567T3 (es) | 1993-10-01 | 1998-04-01 | Scherer Corp R P | Procedimientos y composiciones para administrar fragancias. |
| US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
| AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| AU3846801A (en) | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| CA2449199A1 (en) | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
| CN1250230C (zh) * | 2001-09-30 | 2006-04-12 | 中国药品生物制品检定所 | 海狗油作为制备治脂肪肝药的应用 |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| CA2572344A1 (en) | 2004-07-01 | 2006-01-19 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
| EP1973536A2 (en) * | 2006-01-05 | 2008-10-01 | Reliant Pharmaceuticals, Inc. | Treatment of fatty liver |
| ES2527438T3 (es) | 2006-08-08 | 2015-01-26 | Metabolon, Inc. | Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos |
| JP5341749B2 (ja) * | 2007-03-30 | 2013-11-13 | 興和株式会社 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬 |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2009154230A1 (ja) * | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| EP2415748A4 (en) * | 2009-02-20 | 2013-08-07 | Univ Tokyo | NEW INFLAMMATORY COMPOUNDS |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| WO2012023254A1 (ja) * | 2010-08-19 | 2012-02-23 | 国立大学法人 東京大学 | オメガ３系脂肪酸由来の新規抗炎症性代謝物 |
| WO2012031125A2 (en) | 2010-09-01 | 2012-03-08 | The General Hospital Corporation | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| CN104010637A (zh) | 2011-10-19 | 2014-08-27 | 尊贵科学有限公司 | 含有双同-γ-次亚麻油酸及/或15-羟基二十碳三烯酸的药物组合物及其使用方法 |
| BR112014013098A2 (pt) | 2011-11-29 | 2017-06-13 | Dignity Sciences Ltd | composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos |
| KR102153143B1 (ko) | 2012-01-06 | 2020-09-08 | 옴테라 파마슈티칼스, 인크. | 유리 산 형태의 오메가-3 다중불포화 지방산의 ｄｐａ-농축 조성물 |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| CN110478342A (zh) * | 2012-05-10 | 2019-11-22 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| AU2016370626B2 (en) | 2015-12-18 | 2020-08-20 | Afimmune Limited | Compositions comprising 15-HEPE and methods of using the same |
-
2013
- 2013-01-30 GB GBGB1301626.6A patent/GB201301626D0/en not_active Ceased
- 2013-07-15 ES ES15197389T patent/ES2759448T3/es active Active
- 2013-07-15 RS RS20160118A patent/RS54584B1/en unknown
- 2013-07-15 EP EP13176516.6A patent/EP2762143B1/en active Active
- 2013-07-15 DK DK13176516.6T patent/DK2762143T3/en active
- 2013-07-15 EP EP15197389.8A patent/EP3058943B1/en active Active
- 2013-07-15 PL PL13176516T patent/PL2762143T3/pl unknown
- 2013-07-15 HU HUE13176516A patent/HUE026901T2/en unknown
- 2013-07-15 ES ES13176516.6T patent/ES2564025T3/es active Active
- 2013-07-15 PT PT131765166T patent/PT2762143E/pt unknown
- 2013-07-15 SI SI201330140T patent/SI2762143T1/sl unknown
-
2014
- 2014-01-24 WO PCT/EP2014/051455 patent/WO2014118097A1/en active Application Filing
- 2014-01-24 KR KR1020247001131A patent/KR20240011872A/ko active Application Filing
- 2014-01-24 JP JP2015555661A patent/JP6363104B2/ja not_active Expired - Fee Related
- 2014-01-24 CA CA2897343A patent/CA2897343C/en active Active
- 2014-01-24 CN CN201480006443.XA patent/CN105120872B/zh active Active
- 2014-01-24 SG SG10201806854XA patent/SG10201806854XA/en unknown
- 2014-01-24 MX MX2015009803A patent/MX364646B/es active IP Right Grant
- 2014-01-24 SG SG11201505457PA patent/SG11201505457PA/en unknown
- 2014-01-24 NZ NZ709803A patent/NZ709803A/en not_active IP Right Cessation
- 2014-01-24 KR KR1020157020952A patent/KR102274963B1/ko active IP Right Grant
- 2014-01-24 CN CN201911258822.9A patent/CN111214464A/zh active Pending
- 2014-01-24 KR KR1020227028323A patent/KR102514913B1/ko active IP Right Grant
- 2014-01-24 KR KR1020237009963A patent/KR20230047201A/ko not_active Application Discontinuation
- 2014-01-24 RU RU2015136849A patent/RU2671208C2/ru active
- 2014-01-24 BR BR112015018270A patent/BR112015018270A2/pt not_active Application Discontinuation
- 2014-01-24 KR KR1020217020740A patent/KR102434817B1/ko active IP Right Grant
- 2014-01-24 RU RU2018136872A patent/RU2018136872A/ru not_active Application Discontinuation
- 2014-01-24 AU AU2014211628A patent/AU2014211628B2/en not_active Ceased
-
2015
- 2015-01-29 HK HK15100996.7A patent/HK1200351A1/zh unknown
- 2015-04-24 US US14/695,865 patent/US20150224076A1/en not_active Abandoned
- 2015-07-12 IL IL239893A patent/IL239893A/en active IP Right Grant
- 2015-07-13 ZA ZA2015/05018A patent/ZA201505018B/en unknown
- 2015-07-16 PH PH12015501582A patent/PH12015501582B1/en unknown
- 2015-07-29 MX MX2019005082A patent/MX2019005082A/es unknown
-
2016
- 2016-02-25 CY CY20161100155T patent/CY1117209T1/el unknown
- 2016-02-26 HR HRP20160203T patent/HRP20160203T1/hr unknown
- 2016-03-08 SM SM201600069T patent/SMT201600069B/xx unknown
- 2016-07-21 ZA ZA2016/05125A patent/ZA201605125B/en unknown
-
2017
- 2017-04-06 IL IL251639A patent/IL251639A0/en active IP Right Grant
-
2018
- 2018-06-27 JP JP2018121494A patent/JP2018172409A/ja active Pending
- 2018-07-16 AU AU2018206685A patent/AU2018206685A1/en not_active Abandoned
-
2019
- 2019-04-07 IL IL265876A patent/IL265876A/en unknown
- 2019-07-31 US US16/527,841 patent/US10813903B2/en active Active
-
2020
- 2020-09-16 US US17/022,180 patent/US20210228524A1/en not_active Abandoned
-
2021
- 2021-04-16 US US17/232,862 patent/US20210244697A1/en not_active Abandoned
-
2022
- 2022-03-23 US US17/702,294 patent/US20220347147A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005082A (es) | Composiciones que comprenden 15-ohepa y metodos para usar las mismas. | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| MX2017001279A (es) | Usos y composiciones de la flagelina. | |
| PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX360979B (es) | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. | |
| GEP201706663B (en) | Novel composition for nonalcoholic fatty liver disease (nafld | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
| NZ715201A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| PH12016502050A1 (en) | Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation | |
| MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
| PL423259A1 (pl) | Koniugaty przeciwciało-ureaza dla celów terapeutycznych | |
| MX2015008877A (es) | Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2015005734A (es) | Metodos de tratamiento de enfermedades hepaticas. | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| MX2016002931A (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. |